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INTRODUCTION
Faecal calprotectin (FC) is a biomarker for 
gastrointestinal inflammation. FC testing 
is recommended by gastroenterological 
societies across the globe for its usefulness 
in the diagnosis of inflammatory bowel 
disease (IBD), a chronic inflammatory 
condition requiring specialist treatment.1–5 
However, there is no clear guidance 
on settings, in which it is considered 
appropriate.
In the UK, FC testing was approved 
by the National Institute for Health and 
Care Excellence (NICE) in 2013 for use in 
general practice in patients when referral 
to secondary care is being considered 
and cancer is not suspected (diagnostics 
guidance: DG11)6 to reduce the number 
of unnecessary referrals to colonoscopy. 
The NICE evaluation defined eligibility for 
testing as ongoing abdominal symptoms for 
≥6 weeks in patients aged <45 years. The 
assessment also recommended referral 
of patients with FC levels ≥50 µg/g. At the 
time of publication of the guidance, little 
evidence of FC testing in general practice 
was available. 
Insights into how the FC test may work 
in general practice came from two small 
pilot studies in the north of England funded 
by the NHS Technology Adoption Centre.7 
The findings from these pilot studies mainly 
concerned the theoretical referral pattern of 
patients with abdominal symptoms based 
on test results but did not consider the 
impact of testing on decision making, as 
the working diagnosis and referral decision 
were not influenced by the FC test. The 
guidance was primarily based on evidence 
from secondary care and assumptions on 
test use. The evidence was considered by 
an independent committee (the Diagnostics 
Advisory Committee including two 
consultant gastroenterologists and two 
GPs) that prepared the recommendations 
for NICE. 
A recent systematic review concluded 
that there is still a lack of evidence on the 
defined role of FC testing in the general 
practice pathway for the detection of IBD.8 
Furthermore, early experience with FC 
testing in general practice reported that 
between 26% and 45% of patients with a 
negative FC test result were referred to 
specialist care,9–11 which may question the 
usefulness of FC tests in general practice. 
The aim of this study was to investigate 
the uptake of FC testing into routine 
general practice following NICE guidance, 
to characterise FC test use in light of NICE 
guidance, and to describe the impact of 
FC testing on referral and colonoscopy 
decisions using routine electronic health 
records from UK general practices.
METHOD
Data source
Study data consisted of electronic 
primary healthcare data from The Health 
Improvement Network (THIN). THIN 
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consists of anonymised, longitudinal 
individual-level patient data from >670 UK 
general practices using the Vision practice 
software. In 2015 a total of >14 million 
patients had contributed data to THIN, 
which reflects a coverage of about 6% of 
the UK population.12 Data were included 
into the study from general practices from 
the date that the practice was deemed to 
be reporting all-cause mortality reliably 
compared with national statistics and 
from 1 year after the installation of the 
electronic medical record system.13 For 
additional information on the database see 
Supplementary Appendix S1.
Study design and study population
A retrospective cohort study was 
undertaken of patients who were aged 
≥18 years during the period 1 January 2006 
to 31 December 2016. The study cohort was 
open with patients entering and exiting at 
different times. Patients entered the study 
1 year after they registered with the general 
practice or at age 18 years, whichever came 
later. Patients exited the study at the earliest 
of the following dates: deregistration with 
the practice; death; or 1 January 2017.
Identifying IBD diagnosis, eligible 
symptoms, and investigations
IBD diagnoses were identified using the 
first recorded clinical code for IBD or first 
prescription of IBD-specific medication in the 
patient record (see Supplementary Table S1 
for included drugs and Supplementary 
Table S2 for complete code lists). The 
definition of IBD included ulcerative colitis, 
Crohn’s disease, indeterminate colitis, and 
microscopic colitis to reflect the general 
practice context before confirmatory testing.
Symptoms of interest were abdominal 
complaints that would justify FC testing 
(change in bowel habit, diarrhoea, 
constipation, bloating, and abdominal 
pain). NICE eligibility was defined as a 
relevant recorded abdominal symptom 
followed by a second recording of a relevant 
symptom after ≥6 weeks and <3 months. 
This definition was used to operationalise 
NICE guidance, which stipulate eligibility 
for testing as chronic abdominal symptoms 
lasting ≥6 weeks.6 Clinical code lists were 
adapted from those used in previous 
literature where available.14
All coded records of FC tests were 
considered. Colonoscopies were included 
if they were recorded within 12 months of 
the FC test date. Therapeutic investigations 
and screening colonoscopies were 
excluded. Endoscopy was only included if 
the record specified that it was for lower 
gastrointestinal tract investigations. 
Referral was defined as referral to any 
specialty or any record of a discharge letter, 
out-patient appointment, or admission to 
hospital within 6 weeks of the index FC test. 
For counts of referral and colonoscopy, an 
IBD record was considered referral with 
colonoscopy positive under the assumption 
that an IBD diagnosis is not usually made 
without a confirmatory investigation at a 
secondary care setting.
Analysis
FC test uptake and characterisation of 
patients with a FC test. FC test uptake was 
determined as the total number of patients 
who had an FC test per 1000 population 
including all FC tests recorded between 
2006 and 2016. Uptake by practice was 
determined as a) first-ever FC test per 
practice for each practice over time; and 
b) the number of FC tests ordered per 
1000 practice population by the number of 
practices in THIN between 2006 and 2016. 
FC tests were characterised in terms of 
the patients’ demographics and recorded 
symptoms within the 1 year before testing.
Relationship between patients with an 
FC test, IBD, and eligible symptoms. The 
number of patients with eligible symptoms 
for testing, with an FC test, with an IBD 
diagnosis, and with any combination of 
those three outcomes between 2013 (the 
publication year of FC guidance) and 2016 
have been summarised with the aid of 
a Venn diagram using the online tool 
biovenn.15 First-ever recorded events with 
dates that followed the logical sequence: 
How this fits in
Faecal calprotectin (FC) testing to detect 
inflammatory bowel disease (IBD) was 
recommended for use in UK general 
practice in 2013 to reduce referrals of 
individuals who do not have IBD. The 
recommendations were based on evidence 
from secondary care because evidence 
from general practice on test accuracy, 
test use, and the impact of testing on 
patient management was scarce. This 
study found that 20.7% of FC tests were in 
patients not considered eligible according 
to recommendations. In addition, only 3.1% 
of eligible patients have received FC testing 
since national recommendations were 
published, whereas nearly 50% of patients 
with a negative test result were referred. 
Current national recommendations may 
therefore lack applicability to the general 
practice context and need adjusting.
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symptoms preceding FC testing preceding 
IBD diagnosis, using mutually exclusive 
categories, were used for this.
IBD prevalence with 95% confidence 
intervals (CIs) in patients who underwent 
FC testing was determined for 2013 to 2016 
using age cut-offs between 40 and 60 years 
at the time of testing.
Referral and colonoscopy following FC 
testing. Proportions of referrals within 
6 weeks and colonoscopies within 1 year 
of testing by FC test outcome (FC cut-
off 50 µg/g) were determined. Only first-
ever recorded FC tests without prior IBD 
diagnosis between 2009 and 2016 were 
included. FC tests without numeric results 
in µg/g were excluded from the analysis. 
The proportion of IBD diagnoses in patients 
who were referred and had colonoscopies 
were summarised by FC test result. 
Patients were only included if the complete 
follow-up time was available after testing 
so as not to introduce bias against late 
referrals/colonoscopies in individuals who 
tested negative compared with those who 
tested positive.
All analyses were undertaken in R 
(version 3.6.1) unless otherwise specified. 




The study population consisted of 6 965 853 
adult patients between 2006 and 2016. 
Of these, 17 027 patients (mean age 
44.2 years) had a total of 19 840 FC tests 
recorded. There were 1820 patients who 
had two FC tests and 400 patients who had 
>2 tests. The number of tests per patient 
in the study period ranged from 1 to 13. 
Figure 1 depicts patients who had a FC test 
per 1000 population over time. The first 
FC tests were documented in 2009 with a 
noticeable increase in FC test use in 2013. 
FC test use was still increasing at the end 
of the study period.
Uptake by practice revealed that the 
number of practices recording their first 
FC test increased steeply between 2009 
and 2012, and peaked in 2014 (Figure 2). 
By 2016, 66.8% (n = 493/738) of general 
practices had started using FC testing. The 
majority of practices used <5 FC tests in 
a single year throughout the study period 
(Figure 3). By 2016 the number of tests per 
practice ranged from 0 to >70.
Supplementary Table S3 provides 
a summary of the demographics and 
clinical characteristics of patients who 
had a FC test from 2009 to 2016. About 
one-fifth of tests (20.7%, n = 1253/6051) 
were in patients aged ≥60 years. Pain and 
diarrhoea were the most commonly coded 
abdominal symptoms within the 1 year 
before FC testing. In 2016, just over half 
of the tested patients had any abdominal 
symptoms recorded before testing. Of note, 
only 7.8% (n = 473/6051) of FC test records 
were preceded by a record of symptoms 
eligible for FC testing according to the NICE 
recommendations.6
Patients with a FC test, IBD, and eligible 
symptoms between 2013 and 2016
Of 6 965 853 adult patients, there were 
55 477 who had eligible symptoms for FC 
testing, 13 877 with an FC test record, and 
7640 with an IBD diagnosis between 2013 
and 2016. A total of 2974 patients had a 
Figure 1. Patients who had a FC test per 1000 study 
population by year. FC = faecal calprotectin. 
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Figure 2. Number of practices with first-ever 
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combination of these events leading to a 
total of 74 020 patients with ≥1 of these 
events (Figure 4).
The Venn diagram in Figure 5 shows 
the proportional relationship of the three 
events in the population between 2013 and 
2016. The number of patients with eligible 
symptoms followed by an FC test and an 
IBD diagnosis was small (n = 79/74 020).
Only 3.1% (n = 1720/55 477) of patients 
with eligible symptoms received an FC test. 
Furthermore, only 6.5% (n = 500/7640) of 
patients with an IBD diagnosis had a prior 
FC test. The proportion of FC tests ordered 
in patients without eligible symptoms and 
without subsequent IBD diagnosis was 
much larger. Restricting the analysis to 
the year 2016 (including a total of 15 151 
patients) did not show a change in the 
pattern (Figure 5).
The IBD prevalence in 13 877 patients 
who had a FC test was 3.4% (95% CI = 3.1% 
to 3.7%) (see Supplementary Table S4). 
Adding age as an eligibility criterion showed 
that prevalence was similar using age 
cut-offs from 40 to 60 years, with point 
estimates slightly decreasing. In patients 
who had a FC test, 27.8% (n = 130/468) 
of IBD diagnoses were in patients aged 
≥50 years. 
Referral and colonoscopy following FC 
testing
Of 6 965 853 adult patients, 7084 (0.1%) had 
a first FC test recorded in THIN between 
2009 and 2016. Of these, 4792 (67.6%) had 
at least 12 months follow-up (Figure 4). 
Figure 6 shows the proportion of IBD 
diagnoses in patients who were referred 
and those who received a colonoscopy by 
FC test result for the 4792 patients who had 
a FC test. The main finding was that nearly 
50% (n = 1337/2805, 47.7%) of patients with 
a negative FC test were referred and/or 
received a colonoscopy in the defined time 
periods (compared to 71.3% [n = 1416/1987] 
of patients with a positive FC test), with a 
small yield of IBD diagnoses. 
DISCUSSION
Summary
Uptake of FC testing into general practice has 
been slow. Four years after the publication 
of the national recommendations on FC, 
Figure 3. Number of FC tests by number of practices for 
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only 66.8% of general practices had started 
using FC testing and the frequency of testing 
varied widely across practices. About one-
fifth (20.7%) of tests were carried out in 
patients aged ≥60 years in whom testing 
has not been recommended. Few patients 
followed the anticipated NICE pathway 
(symptoms < FC testing < IBD diagnosis) 
and GPs appeared not to manage patients 
as indicated by the FC test results. Nearly 
50% of patients with a negative FC test were 
referred and/or received a colonoscopy. 
Figure 5. Numbers of patients with eligible symptoms 
for FC testing, a record of FC testing, and/or an 
IBD diagnosis for 2013–2016 and for 2016 only. 
IBD = inflammatory bowel disease. FC = faecal 

























Figure 4. Overview of inclusion and exclusion of 
patients for the two analyses. The relationship between 
symptoms, FC test, and IBD diagnosis (left) and referral 
and colonoscopy following FC testing (right) are 
shown. IBD = inflammatory bowel disease. FC = faecal 
calprotectin. 
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Study findings indicate non-compliance with 
NICE guidance, which suggests insufficient 
information for GPs on who to test and how 
to act on the test result.
Strengths and limitations
THIN is a rich source of routine electronic 
patient records of patients managed in 
general practice and is particularly useful 
in the study of real-world problems.12,17 
The study population covered 6% of the 
UK population meaning that findings are 
expected to be generalisable to UK general 
practice.12 The reported prevalence of 3.4% 
of IBD in patients who had a FC test is 
broadly in line with published figures from 
FC test accuracy studies in UK primary care 
studies,9–11,18–20 and higher than the figures 
for the adult general practice population 
(1.4%) in 2016 in the same dataset.21 
Missing data may have affected 
the current analysis. Secondary care 
investigations and specialist referrals are 
incomplete in general practice records. The 
extent of potential missed IBD diagnoses 
and symptoms because of incorrect/missed 
coding or free-text records in this study is 
not known. Variables to mitigate against 
potential missing data were defined. 
FC test results were missing in 30% 
of recorded FC tests. Imputation methods 
were considered inappropriate because the 
proportion of missing data was too large, 
data were unlikely to be missing at random, 
and data essential for imputation (symptom 
severity, reason for testing, assay type, and/
or referral to gastroenterology) were not 
available.
Operationalising the NICE guidance on 
the eligibility of FC testing was difficult. In 
this study chronic symptoms were defined 
as having two instances of a clinical code 
for any gastrointestinal symptom recorded 
≥6 weeks but <3 months apart. This would 
have missed patients with a free-text note 
concerning ongoing symptoms. The authors 
remain cautious in the interpretation of 
eligibility. 
The end date of this study cohort was 
31 December 2016. Uptake may have 
improved, and GPs may have got better 
at testing the right patients over the past 
4 years. However, the authors do not know 
by how much. The data in this study did not 
show a change in pattern of FC test use 
from 2013 to 2016, and the authors are not 
aware of any major information drive to get 
GPs to use more FC testing and use it more 
appropriately. 
Comparison with existing literature
Adoption of new technologies is supported 
by providing information on the technology’s 
consequences, advantages, and 
disadvantages rather than just information 
about the technology itself.22 The NICE 
guidance insufficiently provides this level of 
information.
NICE guidance recommends testing 
to distinguish IBD from irritable bowel 
syndrome when cancer is not suspected.6 
This narrow population does not reflect 
the broader spectrum of disease found in 
general practice. The variation in numbers 
of FC tests that practices ordered per 
1000 patients may suggest that GPs have 
different thresholds and different reasons 
for testing. 
The NICE evaluation of FC testing 
recommends FC testing for patients aged 
<45 years.23 However, 20.7% of tests were 
carried out in patients aged ≥60 years. 
Furthermore, 27.8% of IBD diagnoses in 
patients who had a FC test were in patients 
aged ≥50 years. This goes in hand with the 
Figure 6. Proportion of FC tests with referral, 
colonoscopy, and IBD diagnosis by FC test outcome (FC 
cut-off 50 µg/g). IBD = inflammatory bowel disease. 
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second reported peak of Crohn’s disease 
onset in those aged between 50 and 
60 years.24 This may support the revised 
cut-off of 60 years for FC testing suggested 
for general practice.25 However, the new 
age cut-off may be in disagreement with 
the guidance on FC test use when cancer is 
not suspected and places the responsibility 
with the GPs to judge whether FC testing is 
appropriate, which requires fundamental 
knowledge on what the FC test measures 
and how to use it. 
NICE guidance recommends referral of 
patients with FC levels ≥50 µg/g. FC testing 
has a high negative predictive value of 99.6% 
(95% CI = 99.3% to 99.7%) at this threshold 
(and a positive predictive value of 8.1%, 
95% CI = 7.1% to 9.2%).26 Nevertheless, the 
present study showed that nearly 50% of 
patients with an FC level <50 µg/g were 
referred into secondary care services. This 
is in agreement with reported estimates 
from several primary care studies.9–11,18,19
The referral of patients who are FC 
negative raises concerns over the impact 
of FC testing on colonoscopy rates as a 
considerable proportion of patients were 
further investigated. However, the number 
of colonoscopies in referred patients with 
FC negative tests varied greatly among the 
present study (13.6%, n = 381/2805) and 
three published studies (19%,11 46%,10 and 
71%9). This suggests that the number of 
potentially unnecessary colonoscopies may 
be at least as dependent on secondary 
care decision making as on the availability 
of FC testing in general practice, and that 
FC testing in primary care does not directly 
influence the decisions by specialists over 
whether to investigate referred patients. 
This present study cannot explain the 
reasons for referring patients with low FC 
levels in whom IBD is unlikely. It suggests 
that GPs have a lack of trust in a FC test 
result or have other reasons for referral, 
which FC testing may not be able to address. 
Implications for practice
The NICE guidance on FC testing may not 
be sufficiently informative and appropriate 
to promote uptake or consistent use of 
FC testing. This may be because, first, 
guidelines describe the test pathway for 
IBD rather than for abdominal pain using 
a diagnostic rather than a symptom-based 
approach. Second, guidelines are not 
sufficiently prescriptive to support a non-
referral. Third, the evidence underlying the 
NICE guidance is not based on the setting 
in which the test is used. Therefore, the 
guidance is unable to provide the evidence 
that reducing the number of referrals to 
colonoscopy can be done at the same quality 
and safety of care. This may have led to non-
compliance with NICE recommendations. 
The resulting lack in the expected reduction 
in colonoscopies may question the cost-
effectiveness of FC testing as it is currently 
used in general practice. 
NICE guidance may need revising and 
updating to make guidance applicable 
to general practice, and to provide more 
information for GPs on test use and test 
interpretation. NICE may need to change its 
approach in formulating guidance for testing 
in general practice. An understanding 
about how a test is used and interpreted 
in general practice is needed to formulate 
applicable guidance.
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